

I appreciate the thoughtful engagement of Karim Mithani and George M Ibrahim with my Comment1 and the substantial work that has gone into their registries.2 Their response, however, addresses a position that I did not take. My Comment stated explicitly that paediatric neuromodulation “will not stop; nor should it”, and that “doing nothing can be the greater harm”.1 We are not at odds over whether to treat. The question is whether our frameworks for consent, follow-up, and outcome measurement are adequate to the task we have set ourselves.
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet